๐Ÿ“–
Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis.
Rong B, Pan H, Fu T, Liu Y, Yang P, Zhang J, Wang Y

Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in Front Pharmacol.

Advertisement
SPONSOR CONTENT
Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Comparative effectiveness and safety of almonertinib in EGFR-mutated non-small cell lung cancer: an integrated evidence synthesis.
Author / Organization Rong B, Pan H, Fu T, Liu Y, Yang P, Zhang J, Wang Y
Subject & Discipline Front Pharmacol
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-31727
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »